Dental and Medical Problems

Dent Med Probl
Impact Factor (IF 2023) – 2.7
Journal Citation Indicator (JCI 2023) - 1.06
Scopus CiteScore (2023) – 4.0 (CiteScore Tracker – 4.9)
Index Copernicus (ICV 2023) – 181.00
MNiSW – 70 pts
ISSN 1644-387X (print)
ISSN 2300-9020 (online)
Periodicity – bimonthly


 

Download original text (PL)

Dental and Medical Problems

2010, vol. 47, nr 2, April-June, p. 199–205

Publication type: review

Language: Polish

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Zastosowanie biochemicznych markerów obrotu kostnego w medycynie ogólnej i stomatologii

Use of Biochemical Markers of Bone Turnover in General Medicine and Dentistry

Piotr Jurkowski1,, Elżbieta Mierzwińska-Nastalska1,, Jolanta Kostrzewa-Janicka1,

1 Katedra Protetyki Stomatologicznej IS Warszawskiego Uniwersytetu Medycznego

Streszczenie

W pracy przedstawiono współczesne zastosowanie markerów obrotu kostnego w medycynie ogólnej i stomatologii. Ich stężenie mierzy się w surowicy, moczu lub płynie stawowym. Wskazuje on na tempo syntezy lub resorpcji tkanki chrzęstnej i kostnej. Informacje te służą do oceny skuteczności leczenia i ryzyka złamań u pacjentów z osteoporozą oraz monitorowania rozwoju chorób nowotworowych kości. W stomatologii dokonuje się pomiarów markera CTX u pacjentów leczonych bisfosfonianami, przed zabiegami chirurgicznymi szczęk. Pozwala to zapobiec powstaniu pozabiegowej martwicy kości. Prowadzone są również prace nad wykorzystaniem wskaźników resorpcji chrząstki do wczesnej diagnostyki osteoartrozy stawów, w tym stawu skroniowo-żuchwowego. Wczesne wykrycie niewidocznych jeszcze radiologicznie nieprawidłowości umożliwiłoby wprowadzenie odpowiedniego leczenia i zapobiegło rozwojowi nieodwracalnych zmian zwyrodnieniowych (Dent Med. Probl. 2010, 47, 2, 199–205).

Abstract

In this article, contemporary use of bone turnover markers in medicine and dentistry was presented. Their level is measured in serum, urine and synovial fluid. It shows the rate of cartilage and bone synthesis as well as resorption. This information is used to estimate effectiveness of treatment and risk of fractures in osteoporotic patients. It enables also to monitor bone neoplasm progression. In dentistry, measurement of CTX marker in patients on biophosphonate theraphy is practiced, before surgical procedures on maxilla and mandibule. It helps to avoid after-operation bone necrosis. There have been many studies carried on the use of cartilage resorption markers for early joint osteoarthrosis diagnosis, including TMJ. Early detection of radiologically invisible disorders would enable to introduce proper treatment and prevent irreversible degenerative changes (Dent Med. Probl. 2010, 47, 2, 199–205).

Słowa kluczowe

markery obrotu kostnego, osteoartroza stawów skroniowo-żuchwowych

Key words

bone turnover markers, temporomandibular joint osteoarthtosis

References (57)

  1. Marowska J., Kobylińska M., L ukaszkiewicz J., Tałajko A., R ymkiewicz-Kluczyńska B., L orenc R.S.: Pyridinium crosslinks of collagen as a marker of bone resorption rates in children and adolescents: normal values and clinical application. Bone 1996, 19, 669–677.
  2. Garnero P.: Bone markers in osteoporosis. Curr. Osteoporos. Rep. 2009, 7, 84–90.
  3. Bollen A.M., Kiyak H.A., Eyre D.R.: Longitudinal evaluation of a bone resorption marker in elderly subjects. Osteoporos. Int. 1997, 6, 544–549.
  4. Greenspan S.L., Parker R.A., Ferguson L., Rosen H.N., Maitland-Ramsey L., Karpf D.B.: Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Miner. Res. 2004, 13, 1431–1438.
  5. Karczmarewicz E.: Wartość diagnostyczna markerów obrotu kostnego. Osteoforum 2006.
  6. Karczmarewicz E.: Markery obrotu kostnego. Nieinwazyjna ocena parametrów jakości kości. Osteoforum 2008.
  7. Bacci G., Picci P., Orlandi M.: Prognostic value of serum alkaline phosphatase in osteosarcoma. Tumori 1987, 73, 331–336.
  8. Coleman R.E.: Metastatic bone disease and the role of biochemical markers of bone metabolism in benign and malignant diseases. Cancer Treat. Rev. 2001, 27, 133–135.
  9. Demers L.M., Costa L., Lipton A.: Biochemical markers and skeletal metastases. Cancer 2000, 88, 2919–2926.
  10. Meier W.G., van der Veer E. Willemse P.H.: Biochemical parameters of bone metabolism in bone metastases of solid tumors. Oncol. Rep. 1998, 5, 5–21.
  11. Ambroszkiewicz J., Gajewska J., Laskowska-Klita T.: Kostna frakcja fosfatazy alkalicznej: charakterystyka i przydatność kliniczna. Med. Wieku Rozw. 2002, 2, 99–110.
  12. Gajewska J., Ambroszkiewicz J., Rchłowska-Pruszyńska M.: Serum markers of bone formation in parients with osteosarcoma. Med. Ped. Oncol. 2002, 35, 319–322.
  13. Burlina A., Rubin D., Secchiero S.: Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase. Clin. Chim. Acta 1994, 226, 151–158.
  14. Van Hoof V.O., Van Osterom A.T., Lepourte L.G.: Alkaline phosphatase isoenzyme patterns in malignant disease. Clin. Chem. 1992, 38, 2546–2551.
  15. Fontana A., Delmas P.D.: Markers of bone turnover in bone metastases. Cancer 2000, 88, 2952–2960.
  16. Jung K., Lein M., Stephan C.: Comparison of 10 serum bone turnover markers in prostete carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int. J. Cancer 2004, 111, 783–791.
  17. Seregni E., Martinetti A., Ferrari L.: Clinical utility of biochemical marker of bone remodeling in patients with metastases of solid tumors. Q.J. Nucl. Med. 2001, 45, 7–17.
  18. Hillner B.E., Ingle J.N., Rowan T., Chlebowski R.T.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 2003, 21, 4042– 4057. 204 P. Jurkowski, E. Mierzwińska-Nastalska, J. Kostrzewa-Janicka
  19. Reszka A.A., Rodan G.A.: Mechanism of action of bisphosphonates. Curr. Osteoporos. Rep. 2003, 1, 45–52.
  20. Marx R.E.: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Maxillofac. Surg. 2003, 61, 1115–1117.
  21. Badros A., Weikel D., Salama A.: Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J. Clin. Oncol. 2006, 24, 945–952.
  22. Mignogna M.D., Lo Russo L.: Osteonecrosis of the jaw associated with bisphospohonate therapy. J. Clin. Oncol. 2006, 24, 1475–1477.
  23. Durie B.G.M., Katz M., Croweley J.: Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 2005, 353, 99–102.
  24. Bamias A., Kastritis E., Bamia C.: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. 2005, 23, 8580–8587.
  25. Ruggiero S.L., Mehrotra B., Rosenberg T.J.: Osteonecrosis of the jaws associated with the use of bisphosponates: A review of 63 cases. J. Oral. Maxillofac. Surg. 2004, 62, 527–534.
  26. Migliorati C.A., Schubert M.M., Peterson D.E., Seneda L.M.: Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. Cancer 2005, 104, 83–93.
  27. Rugiero S., Gralow J., Marx R.E.: Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J. Oncol. Pract. 2006, 2, 7–14.
  28. Lenz J.H., Steiner-Krammer B., Schmidt W.: Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J. Maxillofac. Surg. 2005, 33, 395–403.
  29. Litwiniuk M., Staszkiewicz A.: Martwica kości szczęk po długotrwałym stosowaniu bisfosfonianów. Onkol. Prakt. Klin. 2007, 3, 306–310.
  30. Marx R.E., C illo J.E. Jr, Ulloa J.J.: Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J. O ral Maxillofac. Surg. 2007, 65, 2397–2410.
  31. Young-Min S.A., Cawston T.E., Griffiths I.D.: Markers of joint destruction: principles, problems, and potential. Ann. Rheum. Dis. 2001, 60, 545–548.
  32. Garnero P., Rousseau J.C., Delmas P.: Molecular basis and clinical use of biochemical markers of bone, cartilage and synovium in join diseases. Arthritis Rheum. 2000, 43, 953–968.
  33. Zacher J., Gursche A.: Diagnostik der Arthrose. Orthop 2001, 30, 841–847.
  34. Garnero P., Conrozier T., Christagu S.: Urinary type collagen C-propeptide levels in patients with rapidly destructive hip osteoarthritis. Ann. Rheum. Dis. 2003, 62, 939–943.
  35. Garnero P., Piperino M., Gineyts E.: Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann. Rheum. Dis. 2001, 60, 619–626.
  36. Garnero P., Ayral X., Rousseau J.C.: Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002, 46, 2613–2624.
  37. Reijman M., Hazes J.M., Bierma-Zeinstra S.M.: A new marker for osteoarthritis: cross-selectional and longitudinal approach. Arthritis Rheum. 2004, 50, 2471–2478.
  38. Jung M., Christgau S., Lukoschek M.: Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis. Pathobiology 2004, 71, 70–76.
  39. Lohmander L.S., Atley L.M., Pietka T.A., Eyre D.R.: The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum. 2003, 48, 3130–3139.
  40. Garnero P., Christgau S., Delmas P.D.: The biphosphonate zoledronate decreases type II collagen breakdown in patients with Paget’s disease of bone. Bone 2001, 28, 464–474.
  41. Lehmann H.J., Mouritzen U., Christgau S.: Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann. Rheum. Dis. 2002, 61, 530–533.
  42. Gineyts E., Mo J.A., Ko A.: Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann. Rheum. Dis. 2004, 63, 857–861.
  43. Garnero P., Landewe R., Boers M.: Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum. 2002, 46, 2847–2856.
  44. Garnero P., Gineyts E., Christgau S.: Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum. 2002, 46, 21–30.
  45. Fraser A., Fearon U., Billinghurst R.C.: Turnover of type II collagen and agrecan in cartilage matrix at the onest of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum. 2003, 48, 3085–3095.
  46. De Cunick F., Sabatini M., Renoux V.: Urinary collagen type II C-telopeptide fragments are sensitive markers of matrix metalloproteinase-dependent cartilage degradation in rat adjuvant-induced arthritis. J. R heumatol. 2003, 30, 1561–1564.
  47. Ishikawa T., Nishigaki F., Christgau S.: Cartilage destruction in collagen induced arthritis assessed with a new biochemical marker for collagen type II C-telopeptide fragments. J. Rheumatol. 2004, 31, 1174–1179.
  48. Tanimoto K., Ohno S., Imada M., Honda K., Ohno-Nakahara M., Kapila S., Tanne K.: Utility of urinary pyridinoline and deoxypyridinoline ratio for diagnosis of osteoarthritis at temporomandibular joint. J. Oral Pathol. Med. 2004, 33, 218–223. Biochemiczne markery obrotu kostnego 205
  49. Knudson C.B., Knudson W.: Cartilage proteoglycans. Semin. Cell Dev. Biol. 2001, 12, 69–78.
  50. Hyc A., Osiecka-Iwan A., Joźwiak J., Moskalewski S.: Budowa i niektóre cechy biologiczne chrząstki stawowej. Ortoped. Traumatol. Rehab. 2001, 3, 151–162.
  51. Sandberg M., Vuorio E.: Localization of types I, II, and III collagen mRNAs in developing human skeletal tissues by in situ hybridization. J. Cell Biol. 1987, 104, 1077–1084.
  52. Aigner T., McKenna L.: Molecular pathology and pathobiology of osteoarthritic cartilage. Cell Moll. Life Sci. 2002, 59, 5–18.
  53. Imada M., Tanimoto K., Ohno S., Sasaki A., Sugiyama H., Tanne K.: Changes in urinary bone resorption markers (pyridinoline, deoxypyridinoline) resulting from experimentally-induced osteoarthritis in the temporomandibular joint of rats. Cranio 2002, 21, 38–45.
  54. A merican Association of Oral and Maxillofacial Surgeons: Position paper on temporomandibular joint arthroscopy, 1988.
  55. Board of Trustees. American Association of Oral and Maxillofacial Surgeons: Amended position paper on TMJ arthroscopy, 1988, 20.
  56. Wanyura H., Stopa Z., Brudnicki A., Kostrzewa-Janicka J., Berko-Haas Z.: Diagnostyczno-lecznicza artroskopia stawów skroniowo-żuchwowych. Czas. Stomat. 2001, 54, 674–684.
  57. Shibutani T., Murahashi Y., Tsukada E., Iwayama Y., Heersche J.N.: Experimentally induced periodontitis in beagle dogs causes rapid increases in osteoclastic resorption of alveolar bone. J. Periodontol. 1997, 68, 385–391.
© Wroclaw Medical University